These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 21332118)

  • 1. Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors.
    D'Angelo ND; Kim TS; Andrews K; Booker SK; Caenepeel S; Chen K; D'Amico D; Freeman D; Jiang J; Liu L; McCarter JD; San Miguel T; Mullady EL; Schrag M; Subramanian R; Tang J; Wahl RC; Wang L; Whittington DA; Wu T; Xi N; Xu Y; Yakowec P; Yang K; Zalameda LP; Zhang N; Hughes P; Norman MH
    J Med Chem; 2011 Mar; 54(6):1789-811. PubMed ID: 21332118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-activity relationships of phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: investigations of various 6,5-heterocycles to improve metabolic stability.
    Stec MM; Andrews KL; Booker SK; Caenepeel S; Freeman DJ; Jiang J; Liao H; McCarter J; Mullady EL; San Miguel T; Subramanian R; Tamayo N; Wang L; Yang K; Zalameda LP; Zhang N; Hughes PE; Norman MH
    J Med Chem; 2011 Jul; 54(14):5174-84. PubMed ID: 21714526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and structure-activity relationships of dual PI3K/mTOR inhibitors based on a 4-amino-6-methyl-1,3,5-triazine sulfonamide scaffold.
    Wurz RP; Liu L; Yang K; Nishimura N; Bo Y; Pettus LH; Caenepeel S; Freeman DJ; McCarter JD; Mullady EL; Miguel TS; Wang L; Zhang N; Andrews KL; Whittington DA; Jiang J; Subramanian R; Hughes PE; Norman MH
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5714-20. PubMed ID: 22832322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent, selective, and orally bioavailable inhibitors of mammalian target of rapamycin (mTOR) kinase based on a quaternary substituted dihydrofuropyrimidine.
    Cohen F; Bergeron P; Blackwood E; Bowman KK; Chen H; Dipasquale AG; Epler JA; Koehler MF; Lau K; Lewis C; Liu L; Ly CQ; Malek S; Nonomiya J; Ortwine DF; Pei Z; Robarge KD; Sideris S; Trinh L; Truong T; Wu J; Zhao X; Lyssikatos JP
    J Med Chem; 2011 May; 54(9):3426-35. PubMed ID: 21495671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.
    Li CM; Narayanan R; Lu Y; Hurh E; Coss CC; Barrett CM; Miller DD; Dalton JT
    Int J Oncol; 2010 Oct; 37(4):1023-30. PubMed ID: 20811725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phospshoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: discovery and structure-activity relationships of a series of quinoline and quinoxaline derivatives.
    Nishimura N; Siegmund A; Liu L; Yang K; Bryan MC; Andrews KL; Bo Y; Booker SK; Caenepeel S; Freeman D; Liao H; McCarter J; Mullady EL; San Miguel T; Subramanian R; Tamayo N; Wang L; Whittington DA; Zalameda L; Zhang N; Hughes PE; Norman MH
    J Med Chem; 2011 Jul; 54(13):4735-51. PubMed ID: 21612232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a potent, selective, and orally bioavailable pyridinyl-pyrimidine phthalazine aurora kinase inhibitor.
    Cee VJ; Schenkel LB; Hodous BL; Deak HL; Nguyen HN; Olivieri PR; Romero K; Bak A; Be X; Bellon S; Bush TL; Cheng AC; Chung G; Coats S; Eden PM; Hanestad K; Gallant PL; Gu Y; Huang X; Kendall RL; Lin MH; Morrison MJ; Patel VF; Radinsky R; Rose PE; Ross S; Sun JR; Tang J; Zhao H; Payton M; Geuns-Meyer SD
    J Med Chem; 2010 Sep; 53(17):6368-77. PubMed ID: 20684549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and SAR of novel 4-morpholinopyrrolopyrimidine derivatives as potent phosphatidylinositol 3-kinase inhibitors.
    Chen Z; Venkatesan AM; Dehnhardt CM; Ayral-Kaloustian S; Brooijmans N; Mallon R; Feldberg L; Hollander I; Lucas J; Yu K; Kong F; Mansour TS
    J Med Chem; 2010 Apr; 53(8):3169-82. PubMed ID: 20334367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 4-methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors.
    Liu KK; Bagrodia S; Bailey S; Cheng H; Chen H; Gao L; Greasley S; Hoffman JE; Hu Q; Johnson TO; Knighton D; Liu Z; Marx MA; Nambu MD; Ninkovic S; Pascual B; Rafidi K; Rodgers CM; Smith GL; Sun S; Wang H; Yang A; Yuan J; Zou A
    Bioorg Med Chem Lett; 2010 Oct; 20(20):6096-9. PubMed ID: 20817449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based design, SAR analysis and antitumor activity of PI3K/mTOR dual inhibitors from 4-methylpyridopyrimidinone series.
    Cheng H; Hoffman JE; Le PT; Pairish M; Kania R; Farrell W; Bagrodia S; Yuan J; Sun S; Zhang E; Xiang C; Dalvie D; Rahavendran SV
    Bioorg Med Chem Lett; 2013 May; 23(9):2787-92. PubMed ID: 23506825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors.
    Mortensen DS; Perrin-Ninkovic SM; Harris R; Lee BG; Shevlin G; Hickman M; Khambatta G; Bisonette RR; Fultz KE; Sankar S
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6793-9. PubMed ID: 21978683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based optimization leads to the discovery of NSC765844, a highly potent, less toxic and orally efficacious dual PI3K/mTOR inhibitor.
    Han J; Chen Y; Yang C; Liu T; Wang M; Xu H; Zhang L; Zheng C; Song Y; Zhu J
    Eur J Med Chem; 2016 Oct; 122():684-701. PubMed ID: 27448924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent, selective, and orally bioavailable inhibitors of the mammalian target of rapamycin kinase domain exhibiting single agent antiproliferative activity.
    Koehler MF; Bergeron P; Blackwood E; Bowman KK; Chen YH; Deshmukh G; Ding X; Epler J; Lau K; Lee L; Liu L; Ly C; Malek S; Nonomiya J; Oeh J; Ortwine DF; Sampath D; Sideris S; Trinh L; Truong T; Wu J; Pei Z; Lyssikatos JP
    J Med Chem; 2012 Dec; 55(24):10958-71. PubMed ID: 23199076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigallocatechin gallate (EGCG), a major component of green tea, is a dual phosphoinositide-3-kinase/mTOR inhibitor.
    Van Aller GS; Carson JD; Tang W; Peng H; Zhao L; Copeland RA; Tummino PJ; Luo L
    Biochem Biophys Res Commun; 2011 Mar; 406(2):194-9. PubMed ID: 21300025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of benzenesulfonamide derivatives as potent PI3K/mTOR dual inhibitors with in vivo efficacies against hepatocellular carcinoma.
    Chen Y; Zhang L; Yang C; Han J; Wang C; Zheng C; Zhou Y; Lv J; Song Y; Zhu J
    Bioorg Med Chem; 2016 Mar; 24(5):957-66. PubMed ID: 26819001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of 2-oxatriazines as highly potent pan-PI3K/mTOR dual inhibitors.
    Dehnhardt CM; Venkatesan AM; Chen Z; Delos-Santos E; Ayral-Kaloustian S; Brooijmans N; Yu K; Hollander I; Feldberg L; Lucas J; Mallon R
    Bioorg Med Chem Lett; 2011 Aug; 21(16):4773-8. PubMed ID: 21763134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based design of a novel series of potent, selective inhibitors of the class I phosphatidylinositol 3-kinases.
    Smith AL; D'Angelo ND; Bo YY; Booker SK; Cee VJ; Herberich B; Hong FT; Jackson CL; Lanman BA; Liu L; Nishimura N; Pettus LH; Reed AB; Tadesse S; Tamayo NA; Wurz RP; Yang K; Andrews KL; Whittington DA; McCarter JD; Miguel TS; Zalameda L; Jiang J; Subramanian R; Mullady EL; Caenepeel S; Freeman DJ; Wang L; Zhang N; Wu T; Hughes PE; Norman MH
    J Med Chem; 2012 Jun; 55(11):5188-219. PubMed ID: 22548365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: discovery of PKI-402.
    Dehnhardt CM; Venkatesan AM; Delos Santos E; Chen Z; Santos O; Ayral-Kaloustian S; Brooijmans N; Mallon R; Hollander I; Feldberg L; Lucas J; Chaudhary I; Yu K; Gibbons J; Abraham R; Mansour TS
    J Med Chem; 2010 Jan; 53(2):798-810. PubMed ID: 19968288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel, potent, and selective inhibitors of 3-phosphoinositide-dependent kinase (PDK1).
    Murphy ST; Alton G; Bailey S; Baxi SM; Burke BJ; Chappie TA; Ermolieff J; Ferre R; Greasley S; Hickey M; Humphrey J; Kablaoui N; Kath J; Kazmirski S; Kraus M; Kupchinsky S; Li J; Lingardo L; Marx MA; Richter D; Tanis SP; Tran K; Vernier W; Xie Z; Yin MJ; Yu XH
    J Med Chem; 2011 Dec; 54(24):8490-500. PubMed ID: 22040023
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I).
    Zhang L; Fan J; Chong JH; Cesena A; Tam BY; Gilson C; Boykin C; Wang D; Aivazian D; Marcotte D; Xiao G; Le Brazidec JY; Piao J; Lundgren K; Hong K; Vu K; Nguyen K; Gan LS; Silvian L; Ling L; Teng M; Reff M; Takeda N; Timple N; Wang Q; Morena R; Khan S; Zhao S; Li T; Lee WC; Taveras AG; Chao J
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5633-7. PubMed ID: 21798738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.